title: Hepatocyte growth factor gene transfer into the liver via the portal vein using electroporation attenuates rat liver cirrhosis.
abstract: Although a variety of gene transfer methods to the liver have been designed, there are some problems such as the transfection efficiency and safety. In the present study, we developed a modified method of gene transfer into the liver by infusion of plasmid DNA via the portal vein followed by electroporation. After green fluorescence protein gene transfer, transgene expressions were detected in 24 h, and then maximally at 3 days, and persisted for 3 weeks. Histological analysis revealed that very mild tissue damage was induced in the liver to which electroporation was applied. In the second study, human hepatocyte growth factor (HGF) was more detected in the liver injected with 500 microg of human HGF gene than 100 microg of human HGF gene. However, serum HGF did not increase with 100 or 500 microg of human HGF gene. Moreover, 500 microg of HGF gene transfer into the liver by using this method could achieve the long survival of all dimethylnitrosamine-treated rats and attenuate the fibrous regions in the liver. These results suggest that HGF gene transfer into the liver via the portal vein using electroporation might be one of the useful methods for the treatment of various liver diseases.
authors.affiliation: First Department of Surgery, Gifu University School of Medicine, Gifu, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuno
authors.forename: H
authors.initials: H
authors.lastname: Iwata
authors.forename: Y
authors.initials: Y
authors.lastname: Umeda
authors.forename: H
authors.initials: H
authors.lastname: Takagi
authors.forename: Y
authors.initials: Y
authors.lastname: Mori
authors.forename: A
authors.initials: A
authors.lastname: Kosugi
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: H
authors.initials: H
authors.lastname: Hirose
mesh_terms: D000818:Animals; D004247:DNA / Q000008:administration & dosage*; D018274:Electroporation / Q000379:methods*; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D049452:Green Fluorescent Proteins; D017228:Hepatocyte Growth Factor / Q000235:genetics*; D006801:Humans; D007275:Injections, Intravenous; D008099:Liver / Q000378:metabolism*; D008106:Liver Cirrhosis, Experimental / Q000378:metabolism / Q000628:therapy*; D008164:Luminescent Proteins / Q000235:genetics; D008297:Male; D011169:Portal Vein; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D008164:Luminescent Proteins; D049452:Green Fluorescent Proteins; D017228:Hepatocyte Growth Factor; D004247:DNA